** Shares of Alphamab Oncology drop as much as 58% to HK$2 - the stock's worst fall since listing, and a record low
** Stock last down 40.8%; biggest pct loser on Hang Seng Composite Index and on the Hong Kong bourse
** Co says a phase III clinical trial for its KN046 therapy - KN046-303 - did not reach the preset statistical endpoint for overall survival
** Co says it cannot guarantee that it will be able to develop and ultimately market KN046 successfully
** KN046 is a therapy to treat advanced unresectable or metastatic pancreatic ductal adenocarcinoma (PDAC)
** Hong Kong's healthcare index drops 2%, Hang Seng Composite Index falls 1.3% and Hang Seng Index down 1.5%
** Stock down 56.9% YTD
(Reporting by Donny Kwok)
((donny.kwok@thomsonreuters.com))
Comments